Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/1/2019
SIETES contiene 92636 citas

 
 
 1 a 15 de 15 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]
2.Enlace a cita original Cita con resumen
Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]
3. Cita con resumen
Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]
4. Cita con resumen
Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, for the CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016;374:1145-54. [Ref.ID 100077]
5.Tiene citas relacionadas Cita con resumen
Bolen SD, Maruthur NM. The safety of incretin based drug treatments for type 2 diabetes. BMJ 2016;352:i801. [Ref.ID 100062]
6.Tiene citas relacionadas Cita con resumen
Holman RR, Peterson ED. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2479. [Ref.ID 99762]
7.Tiene citas relacionadas Cita con resumen
Rutter MK, Wright AK, Ashcroft DM. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2478. [Ref.ID 99761]
8. Cita con resumen
Anónimo. Saxagliptin and heart failure: what’s the risk?. NPS MedicineWise 2014:24 de abril. [Ref.ID 97513]
10.Tiene citas relacionadas
White WB, Zannad F. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:484. [Ref.ID 97069]
11.Tiene citas relacionadas
Scirica BM, Braunwald E, Bhatt DL. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:483-4. [Ref.ID 97068]
12.Tiene citas relacionadas Cita con resumen
Standl E. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:483. [Ref.ID 97067]
13.Tiene citas relacionadas Cita con resumen
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. [Ref.ID 96331]
14.Tiene citas relacionadas Cita con resumen
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. [Ref.ID 96330]
15.Tiene citas relacionadas Cita con resumen
Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs - Insights from the rosiglitazone experience. N Engl J Med 2013;369:1285-7. [Ref.ID 96329]
Seleccionar todas
 
 1 a 15 de 15